From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling

Journal of Medicinal Chemistry

Volumn 50, Issue 25, 2007, Pages 6295-6298

  Guba, Wolfgang ^a   Green, Luke G ^a   Martin, Rainer E ^a   Roche, Olivier ^a   Kratochwil, Nicole ^a   Mauser, Harald ^a   Bissantz, Caterina ^a   Christ, Andreas ^a   Stahl, Martin ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CHLORPHENIRAMINE; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; METITEPINE; PHENIRAMINE; SOMATOSTATIN RECEPTOR 5; SOMATOSTATIN RECEPTOR 5 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL GENETICS; COMBINATORIAL LIBRARY; DRUG BINDING; DRUG STRUCTURE; SEQUENCE ANALYSIS;

ASTEMIZOLE; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; HISTAMINE H1 ANTAGONISTS; HUMANS; PIPERIDINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SOMATOSTATIN; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37049017628     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701144e     Document Type: Article

References (25)

1. See: http://www.vpharm.com.
2. Caron, P. R.; Mullican, M. D.; Mashal, R. D.; Wilson, K. P.; Su, M. S.; Murcko, M. A. Chemogenomic approaches to drug discovery. Curr. Opin Chem. Biol. 2001, 5, 464-470.
3. Jacoby, E. A novel chemogenomics knowledge-based ligand design strategy - Application to G-protein-coupled receptors. Quant. Struct.-Act. Relat. 2001, 20, 115-123.
4. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective; Kubinyi, H., Müller, G., Eds.; Wiley-VCH: Weinheim, Germany, 2004.
5. Chemogenomics: Knowledge-Based Approaches to Drug Discovery; Jacoby, E., Ed.; Imperial College Press: London, 2006.
6. Hsu, N.; Cai, D.; Damodaran, K.; Gomez, R. F.; Keck, J. G.; Laborde, E.; Lum, R. T.; Macke, T. J.; Martin, G.; Schow, S. R.; Simon, R. J.; Villar, H. O.; Wick, M. M.; Beroza, P. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints. J. Med. Chem. 2004, 47, 4875-4880.
7. Wadkins, R. M.; Hyatt, J. L.; Wei, X.; Yoon, K. J. P.; Wierdl, M.; Edwards, C. C.; Morton, C. L.; Obenauer, J. C.; Damodaran, K.; Beroza, P.; Danks, M. K.; Potter, P. M. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J. Med. Chem. 2005, 48, 2906-2915.
8. Frimurer, T. M.; Ulven, T.; Elling, C. E.; Gerlach, L.-O.; Kostenis, E.; Högberg, T. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Lett. 2005, 15, 3707-3712.
9. Receveur, J.-M.; Bjurling, E.; Ulven, T.; Little, P. B.; Norregaard, P. K.; Högberg, T. 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5075-5080.
10. Martin, R. E.; Green, L. G.; Guba, W.; Kratochwil, N.; Christ, A. Discovery of the first nonpeptide, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: A chemogenomics approach. J. Med. Chem. 2007, 50, 6291-6294.
11. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., Jr.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Pauli, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
12. Kauvar, L. M.; Higgins, D. L.; Villar, H. O.; Sportsman, J. R.; Engqvist-Goldstein, A.; Bukar, R.; Bauer, K. E.; Dilley, H.; Rocke, D. M. Predicting ligand binding to proteins by affinity fingerprinting. Chem. Biol. 1995, 2, 107-118.
13. Dixon, S. L.; Villar, H. O. Bioactive diversity and screening library selection via affinity fingerprinting. J. Chem. Inf. Comput. Sci. 1998, 38, 1192-1203.
14. Beroza, P.; Villar, H. O.; Wick, M. M.; Martin, G. R. Chemoproteomics as a basis for post-genomic drug discovery. Drug Discovery Today 2002, 7, 807-814.
15. Krejsa, C. M.; Horvath, D.; Rogalski, S. M.; Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME properties and side effects: The BioPrint approach. Curr. Opin. Drug Discovery Dev. 2003, 6, 470-480.
16. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 261-266.
17. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 2005, 1, 389-397.
18. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Biospectra analysis: Model proteome characterizations for linking molecular structure and biological response. J. Med. Chem. 2005, 48, 6918-6925.
19. Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.; Mason, H. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol. 2006, 24, 805-815.
20. See: http://www.cerep.fr/Cerep/Users/index.asp.
21. BioPrint is a registered trademark of Cerep SA. See the following website: www.cerep.com.
22. Patterson, D. E.; Cramer, R. D.; Ferguson, A. M.; Clark, R. D.; Weinberger, L. E. Neighborhood behavior: A useful concept for validation of "molecular diversity" descriptors. J. Med. Chem. 1996, 39, 3049-3059.
23. Daylight Toolkit 4.71, Daylight Chemical Information Systems, Inc., http://www.daylight.com.
24. Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity. J. Med. Chem. 2002, 45, 4350-4358.
25. Concepts and Applications of Molecular Similarity; Maggiora G. M., Johnson, M. A., Eds.; Wiley-Interscience: New York, 1990.